Antigen processing and presentation are the cornerstones of adaptive immunity. B cells
cannot generate high-affinity antibodies without T cell help. CD4+ T cells, which provide …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Abstract Type 1 conventional dendritic (cDC1) cells are necessary for cross-presentation of
many viral and tumor antigens to CD8+ T cells. cDC1 cells can be identified in mice and …

Tumor-associated macrophage (TAM) phagocytic activity is emerging as a new mechanism
to harness for cancer treatment. Currently, many approaches are investigated at the …

Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines
that induce large quantities of high affinity virus-neutralizing antibodies may optimally …

Despite their low abundance in the tumor microenvironment (TME), classical type 1 dendritic
cells (cDC1) play a pivotal role in anti-cancer immunity, and their abundance positively …

Phagocytes, particularly dendritic cells (DCs), generate peptide-major histocompatibility
complex (MHC) I complexes from antigens they have collected from cells in tissues and …

Cancer immunotherapy has emerged as a promising strategy for the treatment of many
forms of cancer by stimulating body's own immune system. This therapy not only eradicates …

The catabolic, degradative capacity of the endo‐lysosome system is put to good use in
mammalian immune responses as is their recently established status as signaling platforms …

The cGAS-STING signaling pathway has emerged as a critical mediator of innate immune
responses, playing a crucial role in improving antitumor immunity through immune effector …